دورية أكاديمية
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study
| العنوان: | Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study |
|---|---|
| المؤلفون: | Andrea Chiricozzi, Giacomo Dal Bello, Niccolò Gori, Lucia Di Nardo, Donatella Schena, Giacomo Caldarola, Martina Maurelli, Clara De Simone, Giampiero Girolomoni, Ketty Peris |
| المساهمون: | Chiricozzi, Andrea, DAL BELLO, Giacomo, Gori, Niccolò, Di Nardo, Lucia, Schena, Donatella, Caldarola, Giacomo, Maurelli, Martina, De Simone, Clara, Girolomoni, Giampiero, Peris, Ketty |
| سنة النشر: | 2023 |
| المجموعة: | Università degli Studi di Verona: Catalogo dei Prodotti della Ricerca (IRIS) |
| مصطلحات موضوعية: | Predicting factors identified patients with dupilumab who could benefit of dose spacing or treatment withdrawal |
| الوصف: | Background: Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for the treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world settings. Objective: This study aimed to identify predictive clinical and demographic factors affecting patient selection for dose spacing or treatment withdrawal due to satisfactory response. Materials and methods: This retrospective study included adult patients with moderate-to-severe AD treated with dupilumab for at least 16 weeks. Descriptive statistics were performed to analyze demographic and clinical variables. Logistic regression models were used to identify predictor variables. Results: A total of 818 adult patients with moderate-to-severe AD was included in the study and 12% (97/818) of them performed dose spacing to 3–4 weeks or treatment withdrawal (8%, 67/818). The presence of non-cutaneous atopic manifestations (OR = 1.59, 95%CI = 1.06–2.38, p = 0.024), prurigo nodularis phenotype (OR = 4.5, 95%CI = 1.87–10.9, p = 0.001) and the age at treatment initiation (OR = 1.82, 95%CI = 1.12–2.94, p = 0.015) were confirmed as the strongest predictors of dose spacing or treatment withdrawal while maintaining dupilumab effectiveness. Conclusion: Our findings contribute to define the patient profile that could maintain the therapeutic response after dose spacing or treatment withdrawal. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | firstpage:1; lastpage:6; numberofpages:6; journal:JOURNAL OF DERMATOLOGICAL TREATMENT; https://hdl.handle.net/11562/1099646Test |
| DOI: | 10.1080/09546634.2023.2235041 |
| الإتاحة: | https://doi.org/10.1080/09546634.2023.2235041Test https://hdl.handle.net/11562/1099646Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.CDAD63F8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1080/09546634.2023.2235041 |
|---|